GC Genome Corporation (KOSDAQ:340450)
South Korea · Delayed Price · Currency is KRW 6,900.00
-100.00 (-1.43%)
Sep 18, 2026, 3:30 PM KST
GC Genome Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 32,637 | 31,534 | 25,888 | 27,292 | 24,114 | 18,498 |
Revenue Growth | 13.71% | 21.81% | -5.15% | 13.18% | 30.36% | 36.46% |
Gross Profit Gross Profit Growth | 15,218 | 14,628 | 11,707 | 13,697 | 10,765 | 7,180 |
Operating Income Operating Income Growth | 1,546 | 1,236 | -1,234 | 160.08 | -3,236 | -2,109 |
Net Income Net Income Growth | 5,415 | 4,044 | -1,257 | -550.1 | -3,763 | 293.2 |
Earnings Per Share EPS Growth | 229.79 | 184.57 | -69.00 | -30.00 | -233.00 | 18.33 |
EPS Growth | 33695.52% | - | - | - | - | - |
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cancer Test Cancer Test Growth | 10,197 | 10,461 | 9,524 |
Obstetrics and Gynecology Obstetrics and Gynecology Growth | 6,525 | 5,269 | 5,159 |
Rare Genetic Disease Rare Genetic Disease Growth | 4,885 | 6,031 | 5,550 |
Checkup Checkup Growth | 4,256 | 4,643 | 3,833 |
Other Other Growth | 24 | 888 | 48 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 42,052 | 40,118 | 6,528 | 8,637 | 17,637 | 25,743 |
Total Debt Total Debt Growth | 3,774 | 4,018 | 4,670 | 11,757 | 10,604 | 14,106 |
Net Cash (Debt) Net Cash Growth | 38,278 | 36,099 | 1,857 | -3,120 | 7,033 | 11,636 |
Net Cash Growth | -11.80% | 1843.62% | - | - | -39.56% | -31.71% |
Net Cash Per Share Net Cash Per Share Growth | 1624.37 | 1647.49 | 101.96 | -170.15 | 435.45 | 727.46 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 2,993 | 1,297 | 377.99 | 3,340 | -1,610 | -67.7 |
Capital Expenditures CapEx Growth | -893.59 | -311.39 | -328.59 | -7,406 | -4,029 | -2,868 |
Free Cash Flow Free Cash Flow Growth | 2,099 | 985.56 | 49.4 | -4,065 | -5,639 | -2,935 |
Free Cash Flow Growth | 523.41% | 1895.10% | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 46.63% | 46.39% | 45.22% | 50.19% | 44.64% | 38.81% |
Operating Margin | 4.74% | 3.92% | -4.76% | 0.59% | -13.42% | -11.40% |
Pretax Margin | 18.25% | 13.16% | -4.35% | -2.98% | -16.06% | 2.20% |
Profit Margin | 16.59% | 12.83% | -4.86% | -2.02% | -15.61% | 1.58% |
FCF Margin | 6.43% | 3.13% | 0.19% | -14.90% | -23.39% | -15.87% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 30.03 | 39.88 | - | - | - | - |
P/FCF Ratio | 77.73 | 163.66 | - | - | - | - |
PS Ratio | 5.00 | 5.12 | - | - | - | - |